Bulk Pharmaceutical API Sources for DESONATE

Bulk Pharmaceutical API Sources for DESONATE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-987-087
AbaChemScene		CS-2228
MedChemexpress MCE		HY-B0248
AvaChem Scientific		638-94-8
AvaChem Scientific		2481
BOC Sciences		638-94-8
Glentham Life Sciences Ltd.		GP4906

DESONATE Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis

Last updated: February 19, 2026

This report analyzes the landscape of bulk active pharmaceutical ingredient (API) sources for Desonate (hydrocortisone butyrate), a topical corticosteroid. It identifies key manufacturers, regulatory compliance, supply chain considerations, and market trends relevant to sourcing Desonate API for pharmaceutical production.

What is Desonate (Hydrocortisone Butyrate)?

Desonate is a topical corticosteroid used to treat skin conditions such as eczema, psoriasis, and dermatitis. The active pharmaceutical ingredient is hydrocortisone butyrate, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It functions by suppressing the release of prostaglandins and leukotrienes, inflammatory mediators, and by inhibiting capillary dilation and edema [1].

Key API Manufacturers and Suppliers

The global supply of hydrocortisone butyrate API is concentrated among a few established manufacturers, primarily in Asia and Europe. These suppliers cater to both generic and branded pharmaceutical companies.

• Major Manufacturers:

  • Indian Companies: India is a significant hub for API manufacturing. Companies like Divi's Laboratories and Sun Pharmaceutical Industries are known for producing a range of corticosteroid APIs, including hydrocortisone butyrate. Their production capacities and adherence to international quality standards are critical for global supply.
  • Chinese Companies: China also plays a substantial role in API manufacturing. While specific public details on hydrocortisone butyrate production by individual Chinese firms can be less accessible, a number of chemical and pharmaceutical manufacturers in China supply intermediates and finished APIs to the global market. Sourcing often involves due diligence to ensure consistent quality and regulatory compliance.
  • European Companies: Some European manufacturers also produce hydrocortisone butyrate, often focusing on higher-purity grades or specialized formulations. Companies like Bachem AG (Switzerland) have a strong reputation in complex API synthesis, though their specific involvement with hydrocortisone butyrate should be directly confirmed.

• Distribution and Trading Companies: In addition to direct manufacturers, several global API distributors and trading companies facilitate the sourcing of hydrocortisone butyrate. These entities often aggregate supply from multiple manufacturers, offering a broader range of product specifications and quantities. Examples include Loba Chemie (India) and Thermo Fisher Scientific, which offer laboratory and bulk quantities.

Regulatory Compliance and Quality Standards

Sourcing Desonate API necessitates strict adherence to international regulatory standards to ensure product safety and efficacy.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP guidelines set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). Compliance is typically demonstrated through site inspections and the issuance of Certificates of GMP Compliance.
• Drug Master Files (DMFs): API manufacturers often submit DMFs to regulatory authorities. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. For hydrocortisone butyrate, a U.S. DMF would be critical for U.S. pharmaceutical companies seeking to use the API in their finished drug products.
• Pharmacopeial Standards: API must meet the specifications outlined in major pharmacopeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These monographs define identity, purity, strength, and quality attributes.
• REACH Compliance (Europe): For APIs imported into the European Union, compliance with Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulations is often required for the substance itself or its components.

Table 1: Key Regulatory Considerations for Hydrocortisone Butyrate API

Regulatory Body	Standard/Requirement	Significance for Sourcing
FDA (U.S.)	Current Good Manufacturing Practices	Mandates quality control in manufacturing. Site inspections and FDA registration are critical.
EMA (EU)	EU GMP, CEP (Certificate of Suitability)	Ensures product quality and safety for the European market. CEPs streamline authorization.
USP	USP Monograph for Hydrocortisone Butyrate	Defines API specifications. Must meet or exceed these standards for U.S. market entry.
Ph. Eur.	Ph. Eur. Monograph for Hydrocortisone Butyrate	Defines API specifications. Must meet or exceed these standards for EU market entry.
ICH Q7	GMP Guide for APIs	International consensus on GMP for APIs, promoting global harmonization.

Supply Chain and Geopolitical Factors

The sourcing of hydrocortisone butyrate API is influenced by global supply chain dynamics, trade policies, and geopolitical stability.

• Geographic Concentration: The significant manufacturing presence in India and China offers cost advantages but also introduces supply chain risks related to single-source dependency, regional regulatory changes, or trade disputes.
• Lead Times and Inventory Management: Standard lead times for bulk API can range from 8 to 20 weeks, depending on the manufacturer's capacity and current demand. Pharmaceutical companies must maintain robust inventory management strategies to mitigate stockouts.
• Quality Audits: Regular quality audits of manufacturing sites by the pharmaceutical company or its designated third party are essential to verify ongoing compliance with GMP and product specifications.
• Intellectual Property: While Desonate itself (as a branded product) may have patent protection, the hydrocortisone butyrate API is a well-established compound, and its generic production is common. The focus for sourcing is on quality, regulatory compliance, and secure supply rather than novel IP.

Market Trends and Pricing

The market for hydrocortisone butyrate API is driven by the demand for generic topical corticosteroids and the ongoing treatment of dermatological conditions.

• Generic Market Growth: The increasing prevalence of skin disorders and the expiration of patents on branded formulations of hydrocortisone butyrate have fueled demand for generic API. This drives competition among API manufacturers, potentially impacting pricing.
• Price Volatility: API pricing can be subject to fluctuations based on raw material costs (e.g., steroidal precursors), energy prices, currency exchange rates, and global supply/demand balances.
• Cost of Goods Sold (COGS): For pharmaceutical manufacturers, the cost of hydrocortisone butyrate API is a significant component of the COGS for finished topical products. Sourcing decisions weigh price against quality, reliability, and regulatory compliance.
• Estimated Pricing: Bulk pricing for hydrocortisone butyrate API typically ranges from $100 to $500 per kilogram, with variations based on purity, volume, supplier, and contractual terms. These are indicative ranges and subject to significant market influence.

Sourcing Strategy Considerations

Developing a robust sourcing strategy for Desonate API involves a multi-faceted approach.

• Supplier Qualification: Rigorous qualification of potential API manufacturers is paramount. This includes reviewing GMP certifications, DMF status, regulatory inspection history, and financial stability.
• Dual Sourcing: Implementing a dual-sourcing strategy, engaging with at least two qualified manufacturers from different geographic regions, can mitigate supply chain disruptions and enhance negotiating power.
• Contractual Agreements: Comprehensive supply agreements should clearly define quality specifications, delivery schedules, pricing mechanisms, change control procedures, and audit rights.
• Supply Chain Visibility: Pharmaceutical companies should strive for transparency in their supply chain, understanding the origin of key raw materials and the manufacturing processes involved in hydrocortisone butyrate production.
• Risk Assessment: Conducting thorough risk assessments for each potential supplier, covering regulatory, operational, geopolitical, and financial risks, is crucial for long-term supply security.

Key Takeaways

• The global supply of hydrocortisone butyrate API is dominated by manufacturers in India and China, with European suppliers also present.
• Strict adherence to GMP, pharmacopeial standards, and regulatory filings (e.g., DMFs) is essential for API sourcing.
• Supply chain risks are associated with geographic concentration, and dual-sourcing is recommended.
• The market is driven by generic demand, leading to competitive pricing, which can range from $100 to $500 per kilogram.
• A strategic sourcing approach includes rigorous supplier qualification, robust contractual agreements, and ongoing risk assessment.

Frequently Asked Questions

• What is the typical lead time for ordering bulk hydrocortisone butyrate API from a qualified manufacturer? Typical lead times can range from 8 to 20 weeks, contingent on the manufacturer's production schedule, order volume, and current global demand.
• Which pharmacopeias must hydrocortisone butyrate API comply with for global markets? API must comply with standards set by major pharmacopeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP), depending on the target market for the finished drug product.
• What is the role of Drug Master Files (DMFs) in sourcing hydrocortisone butyrate API? DMFs contain proprietary information about the API's manufacturing process, quality control, and facilities. Pharmaceutical companies reference these DMFs in their drug product applications to regulatory authorities, expediting the review process by demonstrating the API's suitability.
• Are there specific trade restrictions or tariffs that commonly affect hydrocortisone butyrate API imports? While general tariffs may apply based on the country of origin and destination, specific trade restrictions on hydrocortisone butyrate API are uncommon unless related to broader geopolitical sanctions. However, import regulations and duties should be verified for each specific trade lane.
• How can pharmaceutical companies ensure the long-term stability and quality of their hydrocortisone butyrate API supply? Ensuring long-term stability involves implementing a dual-sourcing strategy with geographically diverse, GMP-compliant manufacturers, conducting regular quality audits, maintaining strong supplier relationships, and establishing clear change control protocols within supply agreements.

Citations

[1] National Center for Biotechnology Information. (2024). PubChem Compound Summary for CID 154895, Hydrocortisone 17-butyrate. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/154895